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Introduction
Th e last decade in global health has seen one of the most 
exciting paradigm shifts in scientiﬁ c research and invest-
ment: “Good science” now means more than rigorous 
appli cation of scientiﬁ c methods toward important 
scientiﬁ c discoveries. Good science has also come to mean 
a deliberate attempt to direct methodologically rigorous 
science toward the disease burden of the underserved, 
across borders. With this move, the role for ethics in 
science is becoming more than an important constraint on 
scientiﬁ c practice and unintended consequences of 
un bridled discovery. Ethics can also inform and shape the 
research agendas for institutions and stakeholders 
interested in improving lives and alleviating suﬀ ering 
among populations whose burden remains under repre-
sented on academic, political, and investment agendas.
Empirical ethics is also emerging as a respected mode 
of inquiry in social science. It provides a critical source of 
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Introduction: Despite the substantial global burden of preterm and stillbirth, little attention has been given to the 
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reproductive decisions and the care of preterm newborns impact the delivery of interventions, and are not well 
understood in low-resource settings. Issues such as how to address the moral and cultural attitudes surrounding 
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burden of preterm birth and stillbirth.
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Conference on Prematurity and Stillbirth. The literature review includes articles in PubMed, Academic Search 
Complete (EBSCO), and Philosopher’s Index with a range of 1995-2008.
Results: Advancements in discovery science relating to preterm birth and stillbirth require careful consideration 
in the design and use of repositories containing maternal specimens and data. Equally important is the need to 
improve clinical translation from basic science research to delivery of interventions, and to ensure global needs inform 
discovery science agenda-setting. Ethical issues in the development of interventions include a need to balance 
immediate versus long-term impacts—such as caring for preterm newborns rather than preventing preterm births. 
The delivery of interventions must address: women’s health disparities as determinants of preterm birth and stillbirth; 
improving measurements of impact on equity in coverage; balancing maternal and newborn outcomes in choosing 
interventions; and understanding the personal and cross-cultural experiences of preterm birth and stillbirth among 
women, families and communities.
Conclusion: Eff orts to improve visibility, funding, research and the successful delivery of interventions for preterm 
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international research ethics helped shape an interdisciplinary global action agenda to prevent preterm birth and 
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empirical data to improve the ethically responsible 
conduct of research, develop culturally and ethically 
sensitive delivery of interventions, identify ethically 
signiﬁ cant blind spots in the measurement of the disease 
burden, and inform policy change. It is in this spirit that 
this scientiﬁ c report integrated ethics into the science of 
maternal, newborn and child health with regard to the 
global burden of preterm birth and stillbirth.
Th is article oﬀ ers a systematic and detailed review of 
the ethical issues that informed, or were raised, during 
deliberations surrounding the report. It considers deeper 
concerns and controversies that will take time to address 
with interdisciplinary inquiry and deliberation. Th is 
article builds upon the existing ethics and social science 
literature in population health, social justice and global 
health, international research ethics, neonatal ethics, and 
health and human rights. Lastly, this article identiﬁ es 
issues raised speciﬁ cally by the global health burden of 
preterm birth and stillbirth that have not been well 
addressed in existing literature.
Despite the signiﬁ cant global burden of preterm birth 
and stillbirth, no systematic international survey of 
relevant ethical and social justice issues exists. Th e 2007 
Institute of Medicine (IOM) report, Preterm Birth: 
Causes, Consequences, and Prevention, includes in its 
appen dices a review of the ethical issues involved in 
preterm birth in the United States [1]. While the IOM 
report is valuable for canvassing ethical concerns of 
preterm birth in high-income countries (HICs), 
signiﬁ cant gaps remain in understanding ethical and 
social justice issues surrounding preterm birth and 
stillbirth in low- and middle-income countries (LMICs).
Th e purpose of the ethics review is to facilitate dialogue 
with scientiﬁ c investigators and to better identify areas 
for targeted normative and empirical bioethics research 
with high impact. Speciﬁ cally, the analysis highlights 
ethical issues that directly or indirectly impact 
deﬁ nitions, discovery science, development, and 
equitable delivery of eﬀ ective interventions to decrease 
the global burden of preterm birth and stillbirth.
Methods
Th is ethics review is based on a comprehensive literature 
review, an ethical analysis of the scientiﬁ c gap analysis on 
preterm birth and stillbirth interventions, and discus-
sions with GAPPS’s Scientiﬁ c Advisory Council and team 
of international investigators, and a community of inter-
national experts on maternal, newborn, and child health 
from the International Conference on Prematurity and 
Stillbirth, Seattle, WA, USA (May 2009). An Ethics and 
Social Justice working group convened to discuss the top 
ethical concerns identiﬁ ed in an early draft of this article 
through ethical cases from the ﬁ eld, oﬀ ered by conference 
participants prior to the meeting. Th e group served an 
advisory role to the broader gap analysis and core investi-
gator team. As such, many of the key concerns raised in 
the ethics working group are represented here. Revisions 
were made to reﬂ ect the working group discussions. Th e 
speciﬁ c recommendations of that group will be published 
as a separate document to represent the full diversity of 
opinions and issues that could not be covered in detail in 
this review. Several of the research questions listed in the 
conclusion of this article have been taken up by the 
working group’s members following the conference.
Th e literature review covered  peer-reviewed articles in 
PubMed, Academic Search Complete (EBSCO), and 
Philosopher’s Index with a range of 1995-2008 for the 
general search terms. Th e following six disciplines are 
included: (1) bioethics, (2) philosophy, (3) social sciences, 
(4) medicine, (5) public health, and (6) epidemiology. 
Commentary and empirical studies appearing in peer-
reviewed medical journals are included, as are scientiﬁ c 
studies containing a substantive discussion of ethical 
issues or equity concerns related to preterm birth or 
stillbirth. Th e review did not include legal or policy 
documents beyond U.S. and international guidelines for 
research ethics with women, pregnant women, vulnerable 
subjects, and ethical guidelines for research in developing 
countries.
Th e following criteria were applied to a comprehensive 
list of ethical and social justice issues related to preterm 
birth and stillbirth to obtain a preliminary list of key 
gaps:
1. Extent and quality of discussion in the peer-reviewed 
literature
2. Degree of consensus on the ethical issues (represented 
in points to consider, clinical guidelines, domestic or 
international policy guidelines)
3. Scope of discussion, from low-, middle-, and high-
income countries
4. Issue may impact basic science or development 
research on preterm birth and stillbirth
5. Issue may impact scale-up or delivery of interventions 
to prevent preterm birth or stillbirth
6. Issue may impact visibility and advocacy surrounding 
preterm birth and stillbirth
7. Issue may impact our understanding of the disease 
burden
Th e preliminary list was presented to the investigator 
team and SAC members for reﬁ nement. Th e following 
topics were identiﬁ ed as priority issues requiring future 
research and public deliberation according to the seven 
criteria above. To correspond with the scientiﬁ c gap 
analysis, the topics are presented here as they arise along 
the translational pathway in preventing preterm birth 
and stillbirth, beginning with deﬁ nitions and discovery, 
through development and delivery. Research questions 
identiﬁ ed throughout the analysis and in the deliberation 
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of the Ethics and Social Justice working group are sum-
marized in Table 1. Th ese questions are intended to shape 
a bioethics research agenda in both social science and 
normative ethical analysis to inform a sustained and 
responsible program to reduce the burden of preterm 
birth and stillbirth within the broader context of 
improving women’s health, as well as maternal, newborn 
and child health.
Results
Ethical issues in defi nitions and measurement
Deﬁ nitions of diseases, their causes, and chosen 
outcomes for research and interventions are shaped by 
the scientiﬁ c community as well as social, political and 
ethical norms across populations and cultures. For 
example, “miscarriage,” “stillborn,” or “early fetal death” 
deﬁ ne cut-oﬀ  points for viability. Medical determination 
of viability is based in empirical science but beliefs about 
the signiﬁ cance of viability are inﬂ uenced by morality, 
culture and politics. Since measuring the burden of 
disease across and within populations is an essential tool 
for raising global visibility among those shouldering a 
greater disease burden, accurately measuring the magni-
tude and extent of particular diseases or health outcomes 
is a critical tool of practical social justice. If aspects of the 
global disease burden are poorly described, disease 
impact may be underestimated, and the suﬀ ering and 
social costs may remain unnoticed and unaddressed.
Table 1. Research questions: ethics and social justice
 Topic Areas Research Questions for Social Science and Normative Ethics
Defi nitions and Visibility: • To what degree are critical scientifi c defi nitions and classifi cation surrounding preterm
Measurement Global Burden Measurement  birth and stillbirth shaped by social and moral norms, and how do controversies over
 Health Reporting & Data  defi nitions aff ect visibility of the disease burden?
 Collection • What are the psychological, social and economic costs associated with increased rates of 
   prematurity in both HICs and LMICs?
  • How can we expand and improve global measures of stillbirth while avoiding implications 
   for the abortion controversy?
Discovery Science Research Ethics • Are there additional ethical issues to consider in the design of biorepositories for the study
 Community Engagement  of preterm birth, and how should these issues be addressed? For example, what are the
 Improving Translation  attitudes and expectations of women who donate to biorepositories for the study of 
   preterm birth and stillbirth?
  • What are the risks for stigmatization surrounding research on infection and preterm birth 
   in vulnerable populations or marginalized communities? What is the potential ethical and 
   social impact of the microbiome model of infection in the context of preterm birth?
  • What are the barriers to eff ective translation between discovery science research on 
   preterm birth and stillbirth and the needs of women and families in LMICs?
  • To what extent can the prevalence of preterm birth or stillbirth be attributed to issues 
   of racial, gender, or economic disparities and how can we target these systematic or 
   structural causes?
Interventions Expanding Outcomes Measures • What is the impact of maternal socioeconomic status on long-term outcomes for preterm
 Socioeconomic Determinants  births?
 Research Ethics • Can we estimate the family and social burden of improving preterm survival, a certain 
   proportion of whom may go on to have signifi cant problems?
  • How should these data inform intervention strategies?
  • What is the subjective experience of disability among preterm birth survivors (accounting 
   for variation across socioeconomic status, culture, lifespan, and parental vs. provider 
   perceptions)?
  • In the design of ethical neonatal intervention trials in developing countries, how can we 
   avoid moral “double standards” in our choice of baseline interventions or control groups, 
   while recognizing real limits to the resources available in low income settings?
Delivery of Medical Decision-Making • In HICs, how should we balance women’s reproductive choices and parental discretion
Interventions Women’s Health  against the impact and costs of preterm birth associated with the use of reproductive
 Cross-Cultural Experience  technology and fertility treatment?
 Health Equity • What ethical dilemmas and value trade-off s do mothers, parents, families, and providers 
   face during pregnancy and with preterm survivors, in settings where women and families 
   lack economic or social safety nets?
  • What are the cross-cultural attitudes and perceptions regarding preterm births, stillbirths, 
   and associated interventions, and how might these beliefs impact the acceptability of new 
   approaches and treatments within a culture?
  • Can we identify better strategies and ethical guidance for balancing the implementation of 
   short-term interventions while working toward more ideal, longer-term solutions in both 
   maternal and newborn interventions?
  • How can we improve and further specify instruments for measuring impact on equity in 
   preterm birth and stillbirth interventions?
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Measuring the global burden of preterm birth and stillbirth
Preterm birth
Measuring the global impact of preterm birth is con-
founded by diﬀ erent abilities to care for the preterm 
neonate and diﬀ erent expectations of when a neonate is 
considered viable. While the deﬁ nition of preterm birth 
is uniform across HICs and LMICs (a birth at <37 
completed weeks of gestation), the expectations of care 
for preterm neonates diﬀ er widely, and often as a func-
tion of inadequate health system and family resources. 
For example, in HICs a 27-week preterm neonate has an 
80-90% chance of survival, with an approximate initial 
direct medical cost of US$150,000. In LMICs with limited 
neonatal intensive care resources and no public or private 
health insurance for families, a 27-week neonate may not 
be considered a candidate for resuscitation. Many who 
then die at this gestational age would not be counted as a 
registered death or stillbirth.
Encouraging uniform deﬁ nitions of preterm birth is 
necessary for sound epidemiology and accurate assess-
ments of the global burden. Consistency is also ethically 
signiﬁ cant. Continued variability in what practically 
counts as a “preterm worth saving” reveals and reinforces 
troubling health disparities. What should be a clinical 
and family decision is instead largely driven by a family’s 
poverty. With this in mind, the ethical lesson from high-
income countries is double-edged. What NICUs have 
made possible in high-income countries serves both as a 
high waterline for what is possible—that having a healthy 
preterm baby might one day cease to be a function of 
being born in a wealthy setting—and a cautious reminder 
that saving lives in the extremely preterm range carries 
signiﬁ cant costs for families and society and requires 
limits.
Inconsistencies in using low birth weight measure-
ments versus gestational age are also in part a function of 
inadequate resources in LICs and rural areas, where the 
majority of births occur in the home, or in facilities with 
inadequate equipment or trained staﬀ  to gather and 
record such information at birth. In these cases, variation 
across measurements of preterm births not only poses a 
challenge for accurately assessing the global disease 
burden of preterm births, but signals underlying health 
disparities in preterm survival in resource-poor settings. 
Distributive justice tends to prioritize critical health 
outcomes, such as decreasing neonatal and maternal 
deaths. Th e signiﬁ cance of improving infrastructure for 
improved health measurement and vital statistics is often 
overlooked when considering moral arguments for 
re distri buting scarce health resources. Funding agencies 
also typically target highly visible outcomes, such as 
reductions in mortality, to demonstrate direct impact due 
to funded interventions. While the results-based ﬁ nan-
cing approach is central to transparent and eﬃ  cient 
investment practices, it can nonetheless reinforce the 
lack of attention to longer-term investments in health 
systems. In the current debate surrounding the develop-
ment of “diagonal,” rather than vertical or horizontal 
invest ment programs in global health [2, 3], it will be 
important to consider the relatively low-cost, high-
impact investments in equipment and training tools 
needed to improve vital registration and gestational age 
measurements. Such investments would vastly improve 
the visibility of the preterm birth burden as a contributor 
to neonatal mortality.
Including causes in preterm birth population health 
measurements can be methodologically challenging but 
ethically signiﬁ cant. Careful calculations of distributive 
justice require careful population health measurement, 
including data on causes. An increase in preterm births 
as a raw measurement is not necessarily an indicator of 
poor population health or health disparities. For example, 
the percentage of preterm births in HICs that are medically 
indicated preterm deliveries, due to a distressed mother or 
fetus, may actually signal a well-funded health system 
and quality perinatal care for high-risk pregnancies. As 
middle-income countries build NICUs and improve 
access to facility births, moderate rises in medically 
indicated preterm births should not necessarily be a 
cause for alarm. While preterm births caused by 
un treated infections or maternal malnutrition would 
likely represent a failure of access in an HIC, they would 
represent a funding or capacity-building gap in an 
LMIC. From the vantage of public health ethics, there is 
also a need to better understand the causal links 
between preterm births and occupational, environ-
mental and personal health risks, such stresses in the 
workplace or smoking. Research on global environ-
mental risk factors is needed to help guide public health 
interventions motivated by claims of social or personal 
responsibility.
In the clinical context, consistent use of cutoﬀ  points 
for viability in preterm births is complicated by varying 
beliefs regarding moral signiﬁ cance of those cutoﬀ 
points. Th ere is a fairly extensive discussion in middle- 
and high-income countries surrounding the ethical 
signiﬁ cance of thresholds of viability and the deﬁ nitions 
of “prematurity” and “extreme prematurity” [4, 5]. Th is 
discussion remains controversial. While it is useful to 
defend a clinical cutoﬀ  point for viability, this will not 
obviate the need for addressing those parents or com mu-
nities viewing this as a moral or religious question, 
regard less of medical opinion or data on clinical out-
comes. In this case, lack of a clear consensus on deﬁ ni-
tions impacts a range of clinical decisions: fetal surgery, 
resuscitation, limitation or withdrawal of treatment, 
palliative care and pain management, and cutoﬀ  points 
for other life-saving interventions.
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Stillbirth
A number of perplexing moral questions arise in the 
measurement of the disease burden associated with 
stillbirth. In global mortality statistics, stillbirths are still 
largely unreported as deaths [6, 7]. WHO estimates that 
of the 10.6 million child deaths before age ﬁ ve in 2001, 
3.9 million occurred before 28 days. Another 3.3 million 
still births were not included in the vital registration 
systems [8, 9]. Health system limitations as well as 
economic and political barriers contribute to under-
report ing. Th ere remain cultural and moral questions 
that may impede eﬀ orts to improve estimates of still-
births worldwide. Making these issues explicit may help 
health oﬃ  cials adequately address cultural and ethical 
debates. Debates over ambiguous information may risk 
derailing positive eﬀ orts to address this high impact issue.
“Stillbirth” is not a well-deﬁ ned term, but a colloquial 
term that is often used inconsistently. Confusion over the 
deﬁ nition of stillbirth, intrapartum death, and mis-
carriage, when collecting reports in and out of facilities, 
makes consistent registration challenging. As discussed 
in the article 1 of this report, stillbirth may refer to late 
fetal death, which is a death after 28 weeks gestation or at 
least 1000 grams birth weight, or it may include early 
fetal death, which is a death after 22 weeks gestation or at 
least 500 grams birth weight. Th irty years ago, the 
minimum gestational age for classiﬁ cation as a stillbirth 
was 28 weeks. Th e deﬁ nition has become progressively 
inclusive by decreasing the minimum required gesta-
tional age. Th ese diﬀ erent measures of stillbirth have had 
a signiﬁ cant impact on infant mortality estimates. Th e 
oﬃ  cial deﬁ nition of a stillbirth in the former Soviet 
Union, for example, led to a 20-25% underestimation of 
the infant mortality rate:
“Babies who were less than 28 weeks, even if they 
showed some signs of life (breathing, heartbeat, voluntary 
muscle movement), were classiﬁ ed as ‘live fetuses’ rather 
than ‘live births’. Only if such newborns survived seven 
days (168 hours) were they then classiﬁ ed as live births. 
If, however, they died within that interval, they were 
classiﬁ ed as stillbirths. If they survived that interval but 
died within the ﬁ rst 365 days they were classiﬁ ed as 
infant deaths [10, 11].”
In the most basic sense, to count a death is to grant 
signiﬁ cance to the life lost. How to count a death and 
whether to count a death is then informed by our beliefs 
about the value of what has been lost. Th is value drives 
the justiﬁ cation for preventing similar future losses. 
Several moral and cultural challenges remain beyond the 
methodological challenges of measuring stillbirths and 
the associated health burden. Politically, in some 
countries, counting early fetal deaths as deaths implies 
that a life worth preserving was lost, and therefore, that 
life at 22 weeks gestation, and perhaps earlier, is a life that 
should not be deliberately taken. Th is has obvious 
implica tions for the abortion debate, and some countries 
have resisted including stillbirths among vital registration 
or mortality statistics for this reason. For the purposes of 
improving vital registration and decreasing stillbirth 
rates, it is worth encouraging a frank discussion about 
this question to either ﬁ nd common ground or to ﬁ nd 
ways around the moral impasse. Of particular concern 
worldwide is avoiding direct or indirect impact on the 
reproductive rights of women by unintentionally fueling 
the abortion debate. Th is could be a case where well-
meaning health policy aimed at improving the health of 
women and neonatal survival has an additional 
un intended consequence of impacting women’s repro-
ductive choices, particularly in those countries where 
reproductive freedom remains tenuous.
Th is debate potentially aﬀ ects how we measure the loss 
of a stillborn within global vital registration systems used 
to allocate health resources. For child and adult deaths 
we can record the age at death, the cause, years of life lost 
(YLL), and the years of healthy life lost due to disability—
also known as Disability-Adjusted Life Year (DALY). In 
addition to lacking suﬃ  cient data on causes for stillbirths, 
measurements of deaths near the time of birth present a 
challenge due in part to puzzles over how to consider the 
life lost [9]. When including stillbirths in global burden of 
disease estimates, it remains unclear whether the best 
approach is to incorporate stillbirths within DALY 
measures, using infant death equivalence or life years 
lost. Th at is, should the loss associated with a stillborn be 
measured in terms of the lost “potential life lived,” and if 
so, how could such a counterfactual measure be made 
meaningful? And if infant or adult-death equivalences are 
used, how should the loss of a stillborn baby be 
discounted? Th at is, by what percentage is a death of a 
stillborn less important than a death of a newborn at 
term, versus a child, versus an adult? Addressing such 
questions is not merely a philosophical exercise, but is 
necessary to develop disease burden measurements that 
accurately represent the magnitude of the burden.
Th e current measurement model used by the GBD and 
many country estimates lists stillbirths as a parallel 
statistic, without trying to incorporate stillbirths into 
DALYS. Using parallel measures risks the burden not 
being taken as seriously in resource allocation decisions, 
typically linked to GBD measures, requiring special 
interest groups to lobby for attention to stillbirths. If 
integrated into DALYs or other aggregate measures, 
stillbirths are more likely to be addressed equally with 
other contributing factors to disease burden in neonatal, 
maternal, and population health. Including stillbirths as a 
function of the mother’s DALY would avoid the puzzles 
in measuring the loss of a stillborn. However, this method 
yields very low numbers and is not considered an 
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accurate measure of the global burden of stillbirth. It is 
worth considering whether we can develop better 
measure ments of the psychological and health impact of 
stillbirths on women (for example, depression or impact 
on fertility).
In summary, several points can be made to avert 
entanglement with the abortion debate and to focus 
instead on the straightforward value of increasing the 
visibility of the disease burden associated with stillbirths, 
with improved vital measurements of stillbirths. At ﬁ rst 
glance, it seems that those who endorse arguments for 
the intrinsic value of preventing early fetal deaths must 
accept certain implications regarding the moral 
permissibility or impermissibility of abortion at viability. 
However, there are a number of compelling reasons for 
preventing stillbirths, none of which invokes abortion:
1. Stillbirth is a signiﬁ cant contributor to the disease 
burden of women and a marker for poor population 
health. Decreasing stillbirths is an important means 
for improving maternal health; understanding the 
causes of stillbirths may help address broader deter-
minants of poor population health.
2. Th e causes and circumstances of many stillbirths are 
reasonably preventable—stillbirths of pregnancies due 
to maternal malnutrition or syphilis, for example. 
Stillbirths that would have resulted in healthy term 
births, but for a preventable maternal infection or 
inadequate prenatal care, are worthy of prevention 
according to most criteria of social justice. Intrapartum 
stillbirths are especially associated with maternal 
morbidity and mortality. Th ese represent 30% of all 
stillbirths and are typically preventable.
3. Eﬀ orts to decrease stillbirths are aimed at preventing 
what are presumably, in most cases, deaths of wanted 
pregnancies.
4. We should distinguish intrapartum stillbirths from 
early intrauterine deaths in the global burden of 
disease measures, thereby making important 
incremental gains by including intrapartum stillbirths 
in global estimates, on par with neonatal deaths. Even 
those who deeply disagree about when life begins will 
concede that it is morally arbitrary to hold that a 
gestationally viable infant who dies during delivery 
does not count at all, whereas an infant that dies after 
being delivered and taking one breath, counts as a 
neonatal death. Th is is not to underestimate the 
challenges of determining the loss associated with 
gestationally early antepartum stillbirths. Th e latter 
problem requires targeted and interdisciplinary 
deliberation, particularly on the issue of unintended 
impact on women’s reproductive freedoms.
For investigators and funding agencies straightforwardly 
interested in decreasing the obvious disease burden of 
stillbirth while sidestepping these diﬃ  cult moral 
questions, the most direct appeal may be made to the 
value of promoting women’s health through the decrease 
of stillbirths, and by promoting the value of healthy births 
at or near term.
Measuring the social, psychological, and economic impact of 
preterm birth and stillbirth
Missing from the global measures of both preterm birth 
and stillbirth is a thorough account of the subjective 
experience of the loss to mothers, parents, and 
communities. While we have some data on the psycho-
logical experience of stillbirth and preterm birth on 
mothers and fathers in HICs [12-15] we have little under-
standing of the cultural and ethnic variation among such 
experiences, or the magnitude of the psychological 
burden on minority or marginalized populations in HICs 
or LMICs.
Social values inform the diﬀ erent labels assigned to a 
pregnancy that do not result in a live birth. With a 
stillborn, cultures may support rituals of grief and 
mourning for the mother or parents, such as naming or a 
burial, yet such rituals are not typically available for a 
miscarriage when the loss may be equally strong in both 
parents [16]. In Pelotas, Brazil in the 1980’s, stillborn 
babies were put in the “next available” coﬃ  n with a dead 
adult and buried together. Th is would save the families 
the cost of a funeral, and the hospital staﬀ  did this 
routinely. As a result, those deaths went unreported for 
many years, until the hospital staﬀ  and undertakers were 
persuaded by the local epidemiologists to stop this 
practice and to begin recording these deaths (Victora and 
Barros, personal communication). A “miscarriage” can 
also imply inadequacy in the mother, as do repeated 
preterm births or stillbirths [16]. In some cultures women 
who have stillborns or early postnatal deaths due to 
preterm birth may be socially stigmatized by their 
husbands, required to undergo cleansing rituals, accused 
of inﬁ delity, or divorced [17]. Additional social science 
research is needed to better understand the social and 
psychological aspects of the disease burden, and to 
improve support interventions to be implemented 
alongside interventions aimed at prevention.
Cultural beliefs and socioeconomic status may also 
impact reporting preterm births and stillbirths. In 
popu lations where high infant mortality rates and high 
stillbirth rates are common, a degree of fatalism may 
impact the experience and reporting of fetal or neonatal 
loss. Th ese are general challenges in measuring the 
more elusive social and psychological impact of disease 
in country-level and global measurements, but there 
remains a speciﬁ c research gap for social science 
researchers interested in capturing the cultural and 
social barriers to reporting both preterm birth and 
stillbirth.
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In HICs where rates of preterm birth may be due in 
part to increased use of Assisted Reproductive Techno-
logies (ART) and fertility treatments, measuring the 
long-term social and economic costs of unregulated use 
of these technologies is a critical step toward decreasing 
preterm birth-related morbidity. In countries like the 
United States where such choices remain largely 
unregulated, little is known about the wider impact of 
preterm births on the health and education systems, and 
on families. In a culture that favors the freedom of choice, 
such health and economic measures would provide an 
important correction to the moral balance between 
maternal and parental choice, preventing harm to others, 
and the social responsibility of parents and providers.
Stillbirth and preterm birth are important indicators of 
child health, women’s health, and social and economic 
inequalities. For this reason, addressing the measurement 
gap is itself an important instrument of social justice. 
Improving methods for measuring rates of preterm birth 
and stillbirth globally and addressing the cultural and 
ethical beliefs surrounding deaths near the time of birth 
will help address a signiﬁ cant blind spot in appreciating 
the complex and signiﬁ cant global burden of these 
outcomes.
Ethical issues in discovery science
Few ethical issues in discovery science related to the causes 
and prevention of preterm birth and stillbirth are unique 
to these outcomes. Most have been thoroughly discussed 
in the literature on basic science research ethics. Th ere are 
three emerging research areas to prevent preterm birth 
that raise special concerns. Th e ﬁ rst is the ethical design 
and use of biorepositories for the purposes of studying 
preterm birth, the second involves microbiome, genome, 
or genetic analysis in the study of infections and preterm 
birth, and the third involves the more general challenges of 
improving clinical translation from basic science research 
in HICs to use in LMICs.
Biorepositories to study preterm birth: informed consent and 
returning results
Th ere are two familiar questions in discussions surround-
ing governance and guidelines on biobanking: How can an 
ethical plan be designed to return results to biobank 
participants and/or a study community? And, how can 
robust informed consent be ensured for participants 
[18-20]? A number of repositories are being established to 
study the causes of preterm birth. Such repositories will 
enroll pregnant women, as well as the ﬁ rst and second 
degree relatives of women who have experienced preterm 
delivery. Biological samples and clinical information are 
collected and typically de-identiﬁ ed to protect the 
conﬁ dentiality of individual participants. Most studies will 
be conducted by secondary investi gators, who are granted 
access to repository samples. As with any other biobank, 
the scope of institutional and investigator responsibility to 
disclose speciﬁ c, aggregate, or incidental ﬁ ndings to 
individual participants (where linked), or participating 
communities, will need to be established in collaboration 
with IRBs and community stakeholders.
Th e rise of genome wide association studies has 
reinvigorated a complex debate that began nearly two 
decades ago regarding the duty to disclose individual 
genetic research results to participants, beyond sharing 
aggregate results in the form of publications or research 
summaries [21-24]. Th e main considerations supporting 
non-disclosure of individual results have been two-fold: 
If a research study is designed to produce general 
knowledge and is not expected to beneﬁ t individual 
participants or expected to yield clinically signiﬁ cant 
ﬁ ndings, then the returning results would run contrary to 
the aims of non-therapeutic, basic science research. 
Further, returning results may unnecessarily harm 
partici pants if they make signiﬁ cant health decisions 
based on highly uncertain, invalid, or poorly interpreted 
data. However, disease advocacy groups, bioethicists, and 
expert policy and regulatory groups have joined in an 
international push for more nuanced guidance based on a 
full range of considerations, including the rights and 
interests that participants may have in knowing 
individual ﬁ ndings, concerns about genetic conﬁ den-
tiality, as well as the potential impact of population-based 
genetic studies [25, 26]. Th ere is currently fair consensus 
on the importance of disclosing only clinically validated 
results and developing a contingency plan for disclosure 
in partnership with an IRB. However, there continues to 
be serious disagreement about the speciﬁ c criteria for 
disclosure and clinical validity [27].
As this debate continues and guidelines for disclosure 
are further developed, researchers and IRBs will need to 
make decisions regarding the plans for disclosure and the 
sharing of research results. During informed consent at 
the time of collection, it will be crucial to clarify whether 
the team plans to return results, whether participants 
may request or decline individual ﬁ ndings, and whether 
samples may be withdrawn at any time. If downstream 
clinical applications are not expected for several years, 
study teams should consider oﬀ ering interventions or 
information that will facilitate healthy pregnancies or 
postnatal care for participants at the time of enrollment. 
As results become available, the usual precautions should 
be taken when returning individual results to clarify 
clinical signiﬁ cance and to oﬀ er genetic or clinical 
support and counseling to help explain the ﬁ ndings, and 
to assist with the decision to inform or not inform 
relatives. Sharing aggregate results may be facilitated by 
password-protected web-based research updates and 
newsletters, to keep participants aware of ongoing 
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aggre gate ﬁ ndings. Th is can include contact information 
for participants with questions about the study and its 
ﬁ ndings. Such a site can also serve as a place for posting 
educational information about healthy pregnancies and 
additional resources for participants. Because of the 
psychological burden that attends preterm birth for 
women and parents globally, biobank institutions may be 
in a position to facilitate social networking among 
participants by taking extra steps to design a biobank 
website that allows for participant-to-participant contact, 
or anonymous posting to a blog. Th is is a way to engage 
participants in long-term studies and to provide beneﬁ t, 
when signiﬁ cant clinical ﬁ ndings (and therefore direct 
beneﬁ t) for individual participants are not expected.
Participants and study communities must consider the 
validity and clinical signiﬁ cance of the results as well as 
its personal meaning of the results to participants and 
study communities. Th e obligations to return results will 
depend upon the scope and duration of the relationship 
between the repository institution, investigators, and 
participants. In the case of studies targeting particular 
communities, especially ethnically-deﬁ ned communities, 
the scope of obligations may be extended to the relevant 
study communities. Care should be taken during 
community engagement to discuss how the research 
ﬁ ndings will improve the health of the community in the 
long-term, and how concerns about potential stigmatiza-
tion will be addressed.
Th ese are familiar ethical questions in biobanking 
research in general. What preterm birth research may 
add to the ethical considerations is an additional concern 
for the expectations and experience of participants. 
Women or couples who have suﬀ ered through one or 
more preterm births, pregnant women who have 
experienced a prior preterm or stillbirth, or have a sister 
or mother who experienced preterm delivery, will likely 
experience heightened anxiety about their pregnancy 
that should be taken into consideration during the 
recruitment process. Similarly, such women may have an 
expectation that by participating in such research, they 
will “ﬁ nd a cure” to prevent preterm delivery for this 
pregnancy or the next one [28]. Attention to these issues 
should shape community engagement, the informed 
consent process, and the eventual return of results.
Microbiome and genome research surrounding preterm birth
Like the Human Genome Project, the goal of the 
Human Microbiome Project in the United States is to 
characterize the human microbiome and create a 
technological and data-rich resource that will enable 
in-depth study of its variation and its inﬂ uence on 
health and disease. For both genomic and microbiome 
research an important target area for application of 
these data is in the ﬁ eld of preterm birth, to understand 
the role of the human microbiome in the perinatal 
period. A recent study concluded that the amniotic 
cavity of women in preterm labor harbors DNA from a 
greater diversity of microbes than previously shown, 
including previously uncharacterized taxa, suggesting a 
causal relationship [29]. Th ese data will likely lead to 
eﬀ orts to characterize the microbial signatures of 
healthy and preterm amniotic cavities, in an eﬀ ort to 
reduce preterm labor and preterm birth. As this 
research moves forward, it will be important to 
remember that this new genetic frontier lies within 
individual women, who may have a range of questions, 
concerns, and needs that should be carefully considered 
in study design and follow-up.
Research applying human genomic or microbiome 
project ﬁ ndings to preterm birth raises several familiar 
ethical and social issues in new ways. Future results 
may challenge historical deﬁ nitions of “contamination,” 
”contagion” and “infection,” by detecting the presence 
of previously unknown microbial species, and by 
detecting microbes not detectable with non-genomic 
techniques. Th ere is potential for individual or group 
stigmatization surrounding demonstrated or suggested 
causal links between infections, especially sexually 
transmitted infections, and increased risks for preterm 
labor or stillbirth. History on the impact of infectious 
diseases in already marginalized populations, such as 
syphilis or HIV, gives reason for caution in dissemina-
ting such ﬁ ndings [30].
Th e burden of preterm birth is often greater in racial/
ethnic minority groups, such as black women in the 
United States or women of lower socioeconomic status 
globally, with poor access to prenatal care and facility 
births. For this reason results of microbiome research in 
particular, and research on the links between infection and 
preterm birth in general, may dispro portionately aﬀ ect 
certain communities of women who in turn may have little 
opportunity to gain from the technological beneﬁ ts of the 
research. Further, both genome and microbiome arrays 
rely on techniques that allow for the detection of a very 
broad range of genetic information, only some of which is 
signiﬁ cant to under standing preterm birth, but with very 
uncertain downstream applications for current research 
partici pants. Retrospective genomic and microbiome 
research, beginning for example with developmental 
delays in preterm survivors and returning to sequence the 
mother’s and baby’s samples, will require similar 
consideration of the impact of these ﬁ ndings in the 
informed consent and dissemination processes.
Improving translation between discovery science in HICs and 
delivery in LMICs
Despite the global impact of preterm birth and stillbirth, 
in terms of lives lost, psychological impact, and long-term 
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economic impact of the morbidities associated with 
preterm survivors, the research agenda for the prevention 
of preterm birth remains signiﬁ cantly underfunded 
compared to other contributors in the global disease 
burden. As global visibility of the disease burden 
associated with preterm births and stillbirths improves, 
one of the emerging challenges will be to improve 
translational applications of discovery science research to 
LMICs [31] and to improve investment in discovery 
research capacity and investigators in LMICs [32].
Eﬀ orts are underway to improve the process of clinical 
translational research—research moving basic science 
research to eﬀ ective clinical interventions—ensuring that 
public investments in basic science research lead to 
improved individual and population health outcomes 
(Figure 1). New, in this analysis, is the concept of a pre-
pathway period, designated as T-0, on the standard T-1 
to T-4 stages of biomedical research, where:
• T-0 phase represents the period during which research 
problems and opportunities are identiﬁ ed,
• T-1 represents discovery science, where opportunities 
to improve health are identiﬁ ed and pursued,
• T-2 the development of potential health applications to 
practice guidelines,
• T-3 the delivery of health applications in practice,
• and T-4 the evaluation of outcomes and impact [33].
A key component of the expanded model reveals the 
often implicit value judgments that inform the choices 
among and within research agendas. Some value 
judgments reﬂ ect important, though often implicit, 
deliberation about the just distribution of scarce research 
resources. Th e expanded model of translation attempts to 
make such value judgments more transparent [34].
With the expanded translational model in mind, a T-0 
challenge in preterm birth research, prior to T-1 setting 
basic science research agendas and funding, is to ensure 
that LIC needs in neonatal and maternal health are 
informing discovery science research agendas in HICs. In 
HICs, incentives shaping research agendas are still largely 
driven by academic advancement within HIC univer-
sities, economic incentives in private industry, and 
politically powerful stakeholders in health funding and 
investment. Ensuring feedback and input from study 
communities, especially in LMICs, requires a cyclical 
view of the translational process, as opposed to the stan-
dard linear, or “pipeline” view [33]. Improving discovery 
science translation for LMICs will also require creative 
thinking for implementing promising systems biology 
research in these settings. Th ose engaged in systems 
biology research in preterm birth might look to the 
examples of HIV, TB, and Malaria research conducted in 
LMICs where strategies have been developed to address 
barriers to training, consistent collection techniques, and 
adequate storage capabilities.
Finally, improving translation on preterm birth 
research from low-income to high-income settings is a 
pressing issue for research priority-setting within HICs. 
Women living in poverty and women from underserved 
ethnic or racial groups in the United States, for example, 
suﬀ er higher rates of preterm birth and infant mortality 
[1, 35]. Such data reinforce the need for a research agenda 
that is shaped by the needs of underserved populations 
wherever they may be found.
Ethical issues in development of interventions
Developing interventions to decrease the burden of 
preterm birth and stillbirth will involve identifying eﬀ ec-
tive interventions along the continuum—from maternal 
health before and during pregnancy, labor and delivery, 
to care of the newborn and mother after birth. Ideally, 
development of interventions will investigate the under-
lying disparities and conditions that contribute to high 
rates of preterm birth and stillbirth in certain 
populations. Th e combined goal is to improve the health 
of women, improve preterm survival and subsequent 
mor bidi ties of preterm survivors, and to reduce still-
births—with special attention to addressing underlying 
health disparities across this continuum. However, taking 
such a holistic approach to maternal and child health in 
the context of preterm birth and stillbirth risks deﬁ ning 
the problem so broadly that it may be diﬃ  cult to make 
progress on any particular outcome, such as increasing 
preterm survival. Study design and implementation for 
the development of eﬀ ective interventions in LMICs 
must also address the constraints of limited resources, 
participant and population vulnerability, and disease 
prevalence unseen in HICs. Most challenging will be to 
Figure 1. Expanded translational model. Source: Starks et al. [33].
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determine what can be done now to address the disease 
burden in a particular context while not losing sight of 
long-term goals of equity in disease burden across and 
within HICs and LMICs. A number of ethical 
considerations arise in development science in preterm 
birth and stillbirth over these issues of investigative scope 
and the need to balance scientiﬁ c rigor with immediate 
versus long-term impact.
Morbidity and outcomes, beyond survival
Improving the lives of children by reducing childhood 
mortality, illness, and disability requires a better under-
standing of the causes and long-term outcomes asso-
ciated with preterm birth. In high-income countries, 
especially the United States, focus on improving the 
survival of preterm infants continues to eclipse the 
prevention of preterm birth. Heralding records for lower 
gestational weight infant survival or successful deliveries 
of multiple births following assisted reproductive inter-
ventions, risks diverting attention from a critical blind-
spot regarding the impact, cost, and challenges associated 
with increasing rates of preterm births. Th ose who 
survive preterm birth and low birth weight have 
increased health risks, including blindness, cerebral 
palsy, behavioral and attention deﬁ cits, and chronic lung 
disease. A number of these health risks have lifelong 
impacts on the children born preterm, and families and 
communities who care for them. Th e burden of such 
outcomes is signiﬁ cant for families who live in poverty 
and lack resources to support children with special 
needs. Th is gives an even greater impetus for identifying 
and implementing eﬀ ective interventions for preventing 
preterm births and stillbirths in low-income commu-
nities. It also reveals the importance of considering the 
long-term consequences of intervention programs. 
Responsible intervention programs aimed at improving 
neonatal survival will address the broad range of commu-
nity concerns for improving neonatal and pediatric care 
and services, if not directly, then through parallel 
partner ships that address structural and health systems 
needs.
Preserving and promoting quality of life requires 
continued research on the long-term outcomes of 
preterm survivors. A number of ethical issues need to be 
addressed when choosing outcome measurements in the 
design of intervention studies: (a) which criteria should 
be used to measure long-term morbidities and quality of 
life among preterm survivors, (b) should we consider the 
availability of diagnostic/intervention services for sur-
vivors of preterm birth with impairments when imple-
ment ing life-saving interventions during the neonatal 
period, (c) what is the impact of maternal socioeconomic 
status on long-term outcomes for preterm birth, and (d) 
what is the subjective experience of disability among 
preterm birth survivors (accounting for variation across 
socioeconomic status, culture, lifespan, and parental vs. 
provider perceptions).
In HICs recent ethical discussions focus on the 
responsible use of assisted reproductive technology 
(ART), a contributing factor in the rate of preterm birth 
in the United States. Despite the link, little attention is 
given to long-term preterm survivor support as a conse-
quence of ART, or the value trade-oﬀ s that parents must 
make, such as weighing the beneﬁ ts of delayed 
reproduction with increased risk for preterm birth. Also 
lacking are reliable estimates for the socioeconomic 
impact of preterm and multiple births associated with 
fertility treatments and ART—the impact on health 
systems, educational systems, families, and survivors. 
Given the value of child survival and the importance of 
preserving and promoting quality of life, addressing the 
long-term outcomes of preterm survivors is critical 
across borders and economic lines.
Similarly, in HICs there is a tendency to focus inter-
vention eﬀ orts on increasingly sophisticated treatment at 
the time of labor or treatment of the preterm infant, and 
relatively little attention to clinical or public health 
interventions on means of prevention for preterm birth 
or stillbirth. Th is may represent the broader tendency in 
many HICs to invest in treatment over prevention—a 
possible bi-product of a health system driven by 
consumer demand. Cultural norms favoring individual 
choice over personal and social responsibility may also 
contribute to the focus on intervening at the point of 
delivery and preterm birth, since public health or 
behavioral interventions may be viewed as impeding free 
choice.
Designing ethical intervention trials in developing countries: 
The “double-standards” debate
In most parts of the developing world, babies are born at 
home and neonatal care is not available to the majority of 
these newborns. Neonatal mortality rates are high in 
these countries, with preterm birth, birth asphyxia or 
injury, and infections representing the leading causes of 
death. Controlled trials on potential neonatal inter-
ventions are essential to address the direct disease burden 
in poor communities and the underlying disparities that 
have led to such disproportionately high rates of infant 
mortality in LICs. When attempting to develop inter-
ventions that will be sustainable within local economic 
constraints and socio-cultural conditions, researchers, 
sponsors, local and international IRBs, and communities 
continue to face one of the most vexing issues in inter-
national research ethics: When the standard of care 
varies within and between countries given resource con-
straints, which standard of care should serve as the 
baseline for determining which interventions can be 
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tested in a study and what, if any, interventions are 
oﬀ ered to participants in a control group?
To illustrate the issue, consider a landmark trial 
conducted in Gadchiroli, India, to address one of the 
leading causes of neonatal mortality in rural India: 
neonatal sepsis [36]. While the standard of care for 
neonatal infections in high-income settings is neonatal 
intensive care and expensive intravenous antibiotics, 
such interventions are not readily available in urban 
centers in India much less in the very rural districts. Was 
it possible to develop lower-cost, safe, and eﬀ ective 
interventions for infants in areas such as Gadchiroli? An 
earlier study of pneumonia management in neonates 
using cotrimoxazol administered by community-based 
health workers had demonstrated a 20% reduction in 
neonatal mortality. Based on these data, researchers in 
the Gadchiroli trial developed a package of home-based 
neonatal care that included the management of neonatal 
sepsis, meningitis, and pneumonia. Investigators hypo-
the sized that this package of interventions would be safe, 
feasible to administer in the ﬁ eld, and could reduce 
neonatal mortality rate by at least 25% in 3 years. Th e 
cluster-randomized intervention trial was conducted 
over 5 years in 86 villages in rural India, including 39 
inter vention villages, and 47 control villages. Th e inter-
vention areas and control areas each included about 
40,000 people. In the 47 control villages, a baseline survey 
was conducted, and standard interventions oﬀ ered. In 
the 39 intervention villages, female village health workers 
were trained in the home-based management of neonatal 
illnesses and provided with a care kit that included basic 
medical supplies, supplies for infection control. For 
newborns suspected of having sepsis, health workers 
administered oral trimethoprim-sulfamethoxazole and 
gentamicin. Health workers in the intervention villages 
tracked pregnant women, observed labor and delivery, 
and visited the home on days 1, 2, 3, 5, 7, 14, 21, 28, and 
any other day the family called in order to examine the 
baby, weigh the child, and treat minor illnesses, sepsis, 
pneumonia, and meningitis [36, 37]. Community consent 
was obtained from the intervention villages and the study 
was subject to an extensive scientiﬁ c and ethical review 
process involving national experts and the Indian Council 
for Medical Research. With this approach, Bang and team 
demonstrated a 72% reduction in neonatal mortality, a 
result that continues to impact national and international 
approaches to neonatal care in low-income settings [38].
And yet, the study came under scrutiny for the 
presence of control villages where only the local standard 
of care was oﬀ ered, since not even the national standard 
of care was considered sustainable [37]. Consider the 
principle put forward in the Declaration of Helsinki, 
which states, “In any medical study, every patient—
including those of a control group, if any—should be 
assured of the best proven diagnostic and therapeutic 
method [39].” On a strict interpretation of this principle, 
it would be impermissible to allow the study of an 
intervention signiﬁ cantly beneath the best standard of 
care, presumably in the Gadchiroli trial, neonatal 
intensive care and frontline intravenous antibiotics [40]. 
Under a strong interpretation of universal standards, this 
trial would never have been approved and thousands of 
infants would have died who were otherwise saved. For 
contexts where there is an urgent need for developing 
low-cost, eﬀ ective and locally sustainable interventions, 
others have argued for a more reasonable interpretation 
of the Helsinki principle that allows for consideration of 
regional context and participant needs when determining 
the ethically appropriate standard of care, while main-
tain ing universal standards against clearly exploita tive 
research with vulnerable populations [38, 41-43].
Th e more profound question regarding the standard of 
care debate is how to pragmatically address urgent local 
needs while not losing sight of higher aspirations to 
address the vast health and economic disparities that will 
continue to fuel the gap between rich and poor in 
neonatal and maternal care. Th at is, how can immediate 
research needs be met in accordance with local stan-
dards, often saving lives and reducing disease burden that 
would otherwise go unaddressed, while ensuring long-
term solutions are pursued? Th e investigators in Gadchiroli 
and other community intervention studies oﬀ er laudable 
examples of how to establish long-term relationships 
with community leaders, study participants, and the 
broader communities to ensure ethical study design that 
is sensitive to the local context, while continuing to ﬁ ght 
for improvements in health for all on the national and 
international stage.
Health disparities and the determinants of preterm birth and 
stillbirth
A sustainable approach to preventing preterm birth also 
requires attention to the systematic causes of preterm 
birth, such as socioeconomic determinants of maternal 
health and healthy pregnancy. Important work has been 
done on the social determinants of health in general. 
Th ere is robust emerging literature on the social deter-
minants of race for preterm birth [44]. Additional 
research is needed on potential solutions to continue 
mapping the global social and economic determinants of 
preterm birth and stillbirth. Th ere are emerging but 
conﬂ icting data on speciﬁ c causal links between types of 
maternal stress and preterm birth, such as depression or 
stressful life events [45, 46]. Th is remains a signiﬁ cant 
research gap in LMICs and for women living in poverty 
or women of racial-ethnic minorities in HICs. One study 
found Black women and American Indian/Alaska Native 
women to have a signiﬁ cantly higher rate of stressful life 
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events in the 12 months before delivery, although this 
racial-ethnic disparity in the experience of stress did not 
contribute signiﬁ cantly to the racial-ethnic disparity in 
preterm birth [46].
Targeting the underlying health disparities in maternal 
health that lead to higher rates of preterm birth and 
stillbirth is important for the sake of women’s health. 
More than a half million women continue to die each 
year in childbirth, often due to inadequate resource 
allocation in maternal health and a complex web of social 
determinants, inadequate clinical capacity, and health 
disparities [47]. Stillbirths are an important indicator of 
maternal health disparities. Measuring the counter-
factual—“these would have been live births if proper 
maternal care had been available”—is challenging but 
crucial from the point of view of distributive justice.
Promoting women’s health, literacy, education, and 
reproductive choices (including contraception and birth 
spacing) are intrinsically valuable, and are also important 
means for lowering rates of preterm birth and stillbirth. 
Given the intimate connection between women’s health 
and the prevalence of preterm birth and stillbirth, 
sustainable interventions will target women’s health and 
socioeconomic well-being, not merely women’s repro-
ductive health or child survival. Developing eﬀ ective 
interventions to ease the global burden of preterm birth 
and stillbirth should be the aim of scientiﬁ c investigators, 
but social science research, public policy, strategic long-
term funding and advocacy have an opportunity to 
address the underlying social and political causes fueling 
this and other aspects of the disease burden in women’s 
health, neonatal survival, and child health beyond 
survival.
Ethical issues in delivery of interventions
Eﬀ ective interventions to prevent preterm birth or 
stillbirth already exist, or have been shown to be eﬀ ective 
in improving preterm survival, but fail to be implemented 
where needed most. Many such interventions, such as 
antenatal steroids or antibiotics, are available at a 
relatively low cost. In this way delivery barriers are in 
some ways more tragic than having no eﬀ ective 
interventions at all. Experts may debate and reﬁ ne 
principles of justice to prioritize eﬀ ective interventions 
but if social, political, or economic barriers prevent 
imple mentation, this represents a failure of practical 
distributive justice. Concerns of social justice are thus 
intimately tied to a rigorous approach to delivery science 
and a delivery gap analysis [48, 49]. Important eﬀ orts 
have been made to develop normative frameworks for 
health priority-setting in general [50]. While there is 
room for debate over principles, immediate and signiﬁ -
cant challenges remain in the practical scale-up of inter-
ventions and in the measurement of impact on equity for 
speciﬁ c diseases [51, 52]. Th ese challenges arise more 
generally in all global health eﬀ orts, but it is worth 
highlighting the particular challenges that arise in the 
prevention of preterm and stillbirth.
Women’s social and health disparities as barriers to delivery 
of interventions
High rates of preterm birth and stillbirth are not only 
markers for poor population health, but should be 
considered sentinel markers for social and health 
disparities facing women in these populations. Among 
the estimated 3.2 million stillborn worldwide, a 
signiﬁ cant number may be due to common, preventable 
causes, such as treatable maternal infections like syphilis, 
asymptomatic bacteriuria, or intrauterine malnutrition 
[53, 54]. In particular, intrapartum stillbirths—30% of all 
stillbirths—are strongly associated with maternal 
morbidity and mortality. Access to prenatal screening for 
high-risk pregnancies, access to emergency obstetric care 
for obstructed labor, and treatments for infection or 
malnutrition often inﬂ uences pregnancy outcomes 
(article 4 in this report [55]). More importantly, barriers 
to safe pregnancy interventions, simple screening, and 
antibiotics, are severely impacting women’s health and 
lives [56]. Women’s socioeconomic status is a known 
predictor of preterm birth and stillbirth, among other 
health outcomes. Literacy, education, and decision-
making empowerment are known to improve women’s 
access to prenatal, delivery, and postnatal care and aﬀ ect 
women’s reproductive choices, such as contraception and 
birth spacing. Th ese choices reﬂ ect a demand for care 
that is necessary once interventions are made available. 
Lack of demand may be a sign of deeper social and 
political challenges facing women in these communities. 
For these reasons, partnering with local organizations to 
address women’s social and health disparities and invest-
ing in health systems are integral to promoting women’s 
health and human rights, as well as a necessary step in 
overcoming barriers to delivery of eﬀ ective preterm birth 
and stillbirth interventions [47, 57, 58].
Within societies where women do not enjoy equal 
social and political status with men and lack social and 
political voice, demand for health services before, during 
and after pregnancy can be seriously reduced. Further 
research is needed to understand women’s speciﬁ c 
concerns about making decisions, traveling to a doctor 
alone, being seen by a male doctor, or disclosing sensitive 
information about sexuality. Because sensitivities and 
concerns about stigma or a husband’s reaction may 
impede the scale-up of infection screening programs, 
such as syphilis screening, there is a need for social 
science research into the context-speciﬁ c and cross-
cultural concerns facing women when choosing to seek 
or not to seek screening and treatment.
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Balancing short- and long-term outcomes: compromises vs. 
ideals
Maternal and newborn advocacy groups can be instru-
mental in addressing resource barriers to improved 
delivery of maternal and newborn interventions. 
However, these advocates do not always see eye-to-eye 
on the best strategies for achieving short- and long-term 
outcomes, especially when maternal health outcomes 
and newborn interventions seem to be in conﬂ ict. Using 
the example of emergency obstetric care, consider two 
diﬀ erent approaches to the problem. From a maternal 
health perspective, ideally, all women would have access 
to quality health facilities for safe deliveries at any risk 
level, so in the event of an unforeseen complication an 
emergency C-section is immediately available that could 
mean the diﬀ erence between saving the life of the mother 
and baby, and losing both. Maternal advocacy groups 
have therefore promoted facility delivery for all women 
[59] and argued that investing in improving the quality of 
home delivery care—either by traditional birth attendants 
(TBAs) or medically trained birth assistants—contributes 
to delayed universal facility care. In most developing 
countries, it will take more than a decade to build the 
infrastructure and skilled staﬀ  necessary for attaining 
such universal access. In the meantime, women continue 
to give birth in the home, where many newborn lives and 
some maternal lives may be saved by cost-eﬀ ective 
interventions that include training of TBAs and/or 
medically-trained health workers. Some newborn 
advocacy groups, therefore, have taken a counter position, 
arguing for the scale-up of such home-based strategies in 
settings where access to facilities is poor while promoting 
improved quality for care at referral facilities. However, 
because the best approach for ensuring maternal health is 
to improve access to resource-intensive, skilled emergency 
obstetric care, some maternal advocacy groups resist this 
less-than-ideal solution.
Th is example illustrates not only the challenge of 
balancing newborn approaches with maternal approaches, 
it represents a broader challenge in global health, namely, 
the need to address immediate and short-term needs 
with non-ideal interventions against longer-term needs 
with more ideal solutions. Holding out for the ideal 
interventions and health systems improvements may 
mean that present needs go unmet by those unwilling to 
scale-up interventions perceived as being less than ideal. 
However, short-term, compromise interventions have a 
tendency to become the accepted, standard intervention, 
given the challenge of shifting behavior, training 
programs and health resources. And the fear, perhaps 
represented by maternal advocacy groups, is that short-
term interventions may undercut the political and 
economic leverage needed to make much more diﬃ  cult, 
sustainable changes in health systems for women.
Further, the controversy over task-shifting reveals the 
tensions between professional stakeholders in maternal 
and child health. In many countries, both physicians and 
nurses unions and professional groups have been strongly 
opposed to, for example, teaching C-sections to tech-
nicians or allowing community health workers prescribe 
antibiotics for newborn sepsis, arguing that the quality of 
care will be inadequate if not outright dangerous. Th is 
issue has in part been addressed with empirical data 
suggesting that task shifting for C-sections [55, 58, 60-62] 
and antibiotic prescription by CHWs [63, 64] have more 
advantages than disadvantages, but it remains an impor-
tant ethical challenge in the delivery of short- and long-
term global health interventions for maternal and 
newborn health.
Poverty and cross-cultural experiences of preterm birth and 
stillbirth as barriers to delivery of interventions
At the systemic and structural level, many of the most 
signiﬁ cant barriers to the delivery of eﬀ ective 
interventions for reducing preterm birth and stillbirth 
reside with the health systems and ministries of health. 
However, solutions to these barriers often reside with 
more powerful areas of government such as the 
ministries of ﬁ nance and foreign aﬀ airs [55, 65]. In many 
LMICs, political instability and inadequate rule of law 
contribute to corruption and lack of accountability in the 
eﬃ  cient and timely allocation of health resources to 
support maternal and neonatal health [66]. Th is is a 
challenge for delivery in any context, but within 
governments or health systems that do not value women 
and children as equal citizens, eﬃ  cient delivery may be 
thwarted by a lack of political will rather than a lack of 
suﬃ  cient funding. Th ese issues reﬂ ect a research and 
policy gap in institutional and health systems design, but 
also a recalcitrant problem in distributive justice and 
health promotion. Th e health and human rights move-
ment oﬀ ers a helpful framework for recasting delivery 
barriers as human rights violations, which can be used as 
leverage among international stakeholders. Recently this 
framework has been applied to the challenges of maternal 
and neonatal health, although it has not been applied to 
preterm birth and stillbirth speciﬁ cally [57]. However, 
additional work is needed to address issues such as the 
impact of international loan restructuring and negotiated 
restrictions on government social spending. Addressing 
these deeper issues will require a critical and multi-
disciplinary discussion about the design of just social and 
political institutions and norms supportive of complex 
global health eﬀ orts.
Poverty and rural geography also impact delivery of 
eﬀ ective and often inexpensive interventions. Families 
living in rural areas of both LMICs and HICs have poor 
access to health facilities. As discussed, one of the major 
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causes of neonatal and maternal mortality in delivery is 
the lack of access to emergency obstetric care, making 
simple geography a critical barrier to delivery of eﬀ ective 
interventions like emergency C-sections. Accessibility 
also impacts availability of the trained staﬀ , drugs and 
equipment needed to support complicated pregnancies. 
Populations living far from urban centers or in extreme 
poverty are also impacted by poor access to health 
information systems for disseminating information on 
nutrition, and to interventions supporting healthy preg-
nan cies and safe birth practices (see Table 1 in article 4 of 
this report [55]). Advanced technology, mobile health 
communications tools, and health systems software are 
no longer viewed as tools of HICs. Instead, novel 
solutions for spanning distance with newer and cheaper 
information technology are becoming critical tools in 
practical social justice, mitigating the disadvantages of 
rural geography and the isolation of poverty [67].
As mentioned previously, a signiﬁ cant gap remains in 
understanding the personal, social, and cross-cultural 
experiences of preterm birth and stillbirth among women 
throughout the world. We do not have a clear 
understanding of women’s, parents’, and communities’ 
experience of preterm birth and stillbirth. Th ese out-
comes are needed to have a complete understanding of 
the burden of disease and to shape culturally appropriate 
and gender-appropriate interventions. While some social 
science work has been done on provider’s experience 
surrounding decision-making and preterm birth, and 
women’s experience of miscarriage, very little work has 
been done to explore experiences such as: suﬀ ering, 
stigma, social attitudes, acceptance and coping. [13, 68] 
Nor do we have adequate cross-cultural studies of these 
issues. Socio-cultural practices surrounding pregnancy 
and birthing practices can impede the implementation of 
training programs and other eﬀ ective interventions that 
conﬂ ict with local practice. Psychological stress and 
social stigma remain barriers to participating in 
prevention interventions. A better understanding of the 
experience of preterm birth and stillbirth is essential to 
the successful and respectful implementation and 
scale-up of interventions.
Improving equity outcome measures in evaluation of 
interventions
Ethically sound intervention programs improve health 
outcomes as well as reduce health disparities within an 
intervention community, population, country or region. 
Despite substantial progress on the development of 
normative frameworks and practical strategies for 
priority-setting in health interventions, [50, 52, 66, 69] 
there are very few evaluations of the eﬀ ectiveness of 
interventions to prevent preterm and stillbirth that 
include assessments of equity as a clear outcome. At a 
very general level, there are three basic domains where 
decisions to scale-up interventions can incorporate 
considerations of equity:
1. Equity of outreach: implementing strategies to reach 
underserved segments of a population
2. Equity of coverage: achieving more comprehensive 
coverage with an intervention across all communities, 
with special attention to improving coverage among 
the poor
3. Equity of impact: demonstrating a decrease in the 
relative disease burden attributable to the intervention 
and outreach-coverage strategies among the poorest in 
the aﬀ ected population [70]
While we have preliminary tools for measuring equity 
impact, many scientists either do not appreciate the 
importance of such measures or the additional analyses 
are not pursued because they often require increases in 
sample size, which can lead to higher study costs.
A recent review of the UNICEF ACSD (Accelerated 
Child Survival and Development) in Mali showed that 
where both the intervention and comparison areas 
showed marked social gradients before the program was 
implemented in 2001, ﬁ ve years later access to antenatal 
care was signiﬁ cantly more equitable in districts with 
ACSD than in other districts. Th is strategy relied heavily 
on outreach sessions aimed at improving access to rural 
mothers living in remote areas, an example of equity in 
outreach [71]. Th is is one of very few examples where 
equity in population coverage was explicitly included in 
outcome measures, and equity of strategy discussed. 
Encouraging the inclusion of all three equity 
considerations for intervention reviews will help improve 
data on equity in maternal and child health, and will help 
inform discussions about improving both equity 
principles and outreach strategies with greater attention 
to diﬀ erent contexts (Figure 2).
In addition, it is important to consider equity measures 
over the long-term and with sensitivity to the “inverse 
equity hypothesis” associated with the introduction of 
new technologies [72], since evidence shows new tech-
nologies tend to be adopted by the wealthy and, therefore, 
are likely to increase health outcome inequities in the 
short-term.
Emerging issues in ethical decision-making and preterm birth
Th ere are several emerging topics in parental decision-
making, personal and social responsibility, and 
prevention of morbidity and mortality associated with 
preterm birth. Th e most signiﬁ cant gap is to distinguish 
the value decisions facing parents and providers in low- 
middle-, and high-income settings without conﬂ ating 
distinct cultural and socioeconomic contexts.
In HICs, successful delivery of interventions to prevent 
preterm birth and stillbirth will come up against social 
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and cultural norms surrounding the freedom of choice in 
reproductive decision-making, particularly in the context 
of the United States. Th ere has been some discussion of 
the ethical issues surrounding the use of assisted repro-
ductive technology (ART) in high-income settings, 
including such issues as reducing multiples, resource 
allocation with expensive technologies, and parental 
choice [73, 74]. Additional work needs to be done to 
address the attendant issues of: low birth weight and 
possible increases in morbidity associated with ART, 
inequity in access to ART as well as access to preterm 
birth support as a consequence of ART, guidelines for the 
responsible use of ART; and attitudes and beliefs 
surrounding the value trade-oﬀ s that parents must make 
surrounding the use of ART, such as delayed reproduc-
tion and increased risk for preterm birth. Emerging areas 
for social science research and the development of ethical 
guidance will explore women’s choices and value trade-
oﬀ s in the workplace, delayed age of birth, occupational 
risks, and other decisions that may increase the likelihood 
of a preterm birth.
Discussion about the appropriate use of neonatal 
technology has dominated in high-income clinical 
settings. [75-81] However, there is very little under-
standing, beyond anecdotal accounts from those engaged 
in intervention eﬀ orts, about the range of moral issues 
that are pressing to women, parents and communities in 
LMICs. More country-speciﬁ c social science data are 
needed that describe the context-speciﬁ c and cultural 
issues facing women, parents and health providers across 
low- and middle-income settings, both rural and urban.
In low-income settings, for example, value questions 
surrounding birth spacing, distance from clinical facility, 
absence from work, or using scarce family resources to 
purchase antibiotics, are important value-trade-oﬀ s 
made everyday by mothers and parents living in rural 
areas often in poverty [82]. Having fewer high-tech 
options does not render value trade-oﬀ s regarding 
reproductive decisions any less important or any less 
diﬃ  cult. Yet, there is almost no discussion of these 
challenges in the bioethics literature, and a copious 
discussion on value decisions in the use of NICUs, 
resuscitation, life-saving drugs, and other perinatal and 
neonatal interventions readily available in HICs. Th is is 
not to say that the ethical discussions surrounding the 
HIC dilemmas are unimportant, but rather, to highlight 
parallel and as yet invisible dilemmas occurring in low-
income settings.
In middle-income settings, or transitional health 
systems, more data are needed to describe potential 
socioeconomic and cultural barriers to scale-up delivery 
of eﬀ ective interventions to prevent preterm birth and 
stillbirth. Since out-of-pocket payments remain the 
primary means of ﬁ nancing health care—including child-
birth in most of Africa and Asia [55, 83, 84]—attention is 
needed on the dilemmas facing mothers, parents and 
families in these regions, including special attention to 
gender issues in cultures that do not value girls [85]. 
Unlike most low-income communities, skilled health 
workers, access to facilities, and standard interventions 
and equipment are available in transitional economies. 
However, unlike most high-income countries, third party 
or state-sponsored payment of these services is not 
available. Value trade-oﬀ s pertaining to prenatal care and 
monitoring for high-risk pregnancies, C-sections, or 
decisions regarding life-saving interventions for preterm 
Figure 2. Coverage with 3+ Antenatal Visits in HID (Intervention) and Comparison Districts. Source: Bryce et al. 2008 [71].
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newborns will include diﬃ  cult economic decisions for 
the parents and family, as well as the provider [86]. As in 
HICs, having better data on long-term morbidity of 
preterm survivors will be critical for parents and 
providers to make informed decisions during pregnancy 
and at the time of birth. However, better data on 
outcomes will not address the lack of health systems and 
economic support for families in LMICs aimed at 
preventing preterm birth and stillbirth, or at supporting 
preterm survivors.
In transitional socioeconomic regions there may also 
be resistance to accepting eﬀ ective low-cost interven-
tions, precisely because they are perceived to be low-cost 
and low-tech. Consider, for example, Kangaroo Mother 
Care (KMC), a very low-cost, low-tech intervention that 
encourages direct skin-to-skin contact between new-
borns and mothers shown to support preterm survival 
(article 4 in this report [55]). An international survey of 
trainees in KMC from 25 LMICs reported several 
cultural and socioeconomic barriers to implementing 
this intervention, including the perception that KMC is 
the “poor man’s alternative” to more sophisticated care. 
Trainees also reported objections to exclusive breast-
feeding, given the perceptions among some that formula 
feeding is more modern and sophisticated [55, 87]. Th ere 
is as yet very little discussion of these dilemmas in the 
bioethics and social science literature. Th is represents an 
important area for future work.
Th ere is a well-developed model for addressing ethical 
dilemmas that require balancing maternal autonomy in 
reproductive decisions with the interests of the 
developing fetus or infant [88]. Th e “balancing interests” 
framework has arisen in the context of caesarean 
deliveries, fetal surgery, brain death in pregnant women, 
maternal illness during pregnancy, intrauterine inter-
ventions, and infertility treatments. While oﬀ ering 
valuable guidance in maternal-fetal conﬂ icts and other 
decisions surrounding preterm delivery, much contro-
versy remains over the best way to resolve maternal-fetal 
conﬂ icts that involve situations due to circumstances out 
of one’s control, such as being born into poverty. Known 
links between occupational and environmental stressors 
and preterm birth [89], for example, raise the previously 
discussed concerns about health disparities and preterm 
birth, and pose a challenge for maternal autonomy con-
strained by the tragic exigencies of poverty. Th e 
maternal-fetal interests model does not oﬀ er adequate 
guidance for such structurally determined choices 
surrounding pregnancy and warrants further discussion 
and research. Th e framework is also rooted in Western 
ethical traditions based on conﬂ ict and balance between 
opposing prima facie values or moral principles. Th ere 
are many other rich ethical traditions that may cast these 
diﬃ  cult choices surrounding preterm birth diﬀ erently 
and can contribute to more culturally-appropriate ethical 
guidance on delivery of interventions. We need to 
encour age research and dialogue in this area to under-
stand these variations.
Socioeconomic and cultural barriers to discontinuing 
ineff ective interventions
Among the barriers to improving delivery of eﬀ ective 
interventions to prevent preterm birth and stillbirth is 
how to discontinue practices and interventions that have 
been shown to be ineﬀ ective or harmful. Th is is a 
challenge in eﬀ ective delivery in any area, but in the 
context of pregnancy it raises several ethical questions 
discussed in article 4 of this report [55].
Many entrenched but ineﬀ ective or harmful practices 
in rural and developing settings may be rooted in cultural 
practices surrounding childbirth. In middle- and high-
income settings, overuse of ineﬀ ective or harmful inter-
ventions may reﬂ ect mothers’ and families’ demand for 
particular services, such as cesarean sections. Particularly 
in transitional health systems, such as in India, demand 
for such services may represent a broader or symbolic 
desire for status that comes with an increase in 
medicalized care [90]. Changing practices requires not 
only overcoming entrenched behavior but also the inertia 
and expense of established public health training 
programs. Retraining will also require sensitivity and 
engagement with existing cultural practices. In high-
income or transitional economic settings discontinuing 
ineﬀ ective interventions will mean curbing the prefer-
ences and demand of women, parents and providers. In 
the case of elective cesareans attempts to curb overuse 
may be misinterpreted as placing unfair limits on 
women’s reproductive choices. Th is case and others 
illustrate the critical importance of gathering and 
dissemi nating good data on ineﬀ ective interventions in a 
way that addresses social and cultural barriers to 
abandoning harmful or ineﬀ ective interventions.
Conclusion
In the process of reviewing the scientiﬁ c, medical, ethics, 
and social science literature on preterm birth and 
stillbirth a number of questions for research, normative 
analysis, public deliberation, or policy development have 
emerged (See Table  1). Ensuring these questions are at 
the top of the global health research, policy and bioethics 
agendas will contribute to a more thoughtful approach in 
our eﬀ orts to prevent global preterm birth and stillbirth. 
Clear bioethics research gaps remain along the research 
and delivery pathway. Addressing these gaps need not be 
an impediment to moving forward on the science, but 
rather has signiﬁ cant potential to support the eﬀ ort. 
Particularly as attempts are made to consider diagonal 
funding and intervention programs—investment 
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strate gies in health systems development alongside 
targeted, or vertical, eﬀ orts to improve speciﬁ c health 
outcomes—partnerships with social scientists and 
bioethicists can be especially valuable as the trade-oﬀ s 
required in com peting programs represent signiﬁ cant 
value judg ments. Bioethics has an opportunity to 
generate empirical data, shape public deliberation, and 
inform institutional changes and resource allocation 
decisions. Th is is needed to successfully deliver improved 
interventions for preventing preterm birth and stillbirth 
while addressing the deeper social, economic, and 
political issues that impact this important area in 
maternal, newborn and child health.
Considering preterm birth and stillbirth without 
borders with cross-cutting attention to HICs and LMICs, 
highlights important global diﬀ erences in prevalence and 
causes but also identiﬁ es critical common ground. 
Globally, there is a common need to improve visibility of 
the complex and substantial disease burden associated 
with preterm births and stillbirths. Th ere is a shared need 
to better understand the downstream impact on mothers, 
parents, preterm survivors, as well as communities, 
health systems, and educational systems. Th e challenge is 
exciting because it oﬀ ers an opportunity to improve lives 
and address health disparities on several critical measures 
at once: neonatal survival, childhood morbidity and 
quality of life, women’s health and quality of life, parental 
and family health. Identifying ethical common ground 
and encouraging public deliberation on areas of 
continued controversy can help shape a global research, 
development, and delivery agenda to prevent preterm 
birth and stillbirth.
Th e next and ﬁ nal article in this report presents an 
interdisciplinary action agenda to prevent preterm birth 
and stillbirth, and to improve related health outcomes 
globally [91].
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